Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia; School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Semin Oncol. 2022 Apr;49(2):178-181. doi: 10.1053/j.seminoncol.2022.04.003. Epub 2022 Apr 29.
Equity in oncology clinical trial participation has been declared a global priority. Australia is a key stakeholder in the global clinical trials sphere and managed to maintain high clinical trial activity during the COVID pandemic. Despite these successes, there is paucity of understanding about what influences clinical trial participation in Australia. In the international context, systematic reviews have highlighted that sociodemographic barriers, access to health care, clinical trial inclusion criteria, and attitudes of physicians and patients are factors which influence oncology trial participation. Exploring the factors in Australian health services which influence trial participation is now of significant importance. The lack of clear evidence directly highlights a need to assess the factors that influence oncology trial participation in Australia. We call for review of existing data to identify future directions in Australia which will potentially give deeper insights for the international clinical trial community.
肿瘤学临床试验参与的公平性已被宣布为全球优先事项。澳大利亚是全球临床试验领域的重要利益相关者，并成功地在 COVID 大流行期间保持了高临床试验活跃度。尽管取得了这些成功，但对于哪些因素影响澳大利亚的临床试验参与度，人们的了解仍然有限。在国际背景下，系统评价强调了社会人口障碍、获得医疗保健的机会、临床试验纳入标准以及医生和患者的态度是影响肿瘤试验参与度的因素。探索影响澳大利亚卫生服务中试验参与度的因素现在具有重要意义。缺乏明确的证据直接凸显了需要评估影响澳大利亚肿瘤学试验参与的因素。我们呼吁审查现有数据，以确定澳大利亚未来的方向，这可能为国际临床试验界提供更深入的见解。
